President Cyril Ramaphosa launched the national rollout of Lenacapavir, a long-acting injectable HIV prevention drug, in Secunda, Mpumalanga, on June 5, 2026 [1].
The introduction of this medication marks a significant shift in public health strategy by providing a durable alternative to daily oral preventatives. This transition aims to increase adherence rates and reduce the frequency of clinic visits for high-risk populations.
The launch took place on Friday in the Mpumalanga province [1], [2]. Lenacapavir is designed to provide long-term protection against HIV infection through a single injection administered at extended intervals, a departure from traditional preventative methods.
Government officials said that the rollout is intended to strengthen South Africa's overall fight against HIV/AIDS [1], [2]. By diversifying the available prevention tools, the health system seeks to reach more citizens and lower the rate of new infections across the country.
The event in Secunda serves as the starting point for a broader distribution effort [3]. The administration intends to integrate the injectable drug into existing health infrastructure to ensure equitable access for those most vulnerable to the virus.
Public health experts said the medication is a potential game-changer for prevention [2]. The long-acting nature of the drug addresses the logistical and social challenges associated with daily medication, such as stigma and forgetfulness.
“President Cyril Ramaphosa launched the national rollout of Lenacapavir”
The shift toward long-acting injectables like Lenacapavir represents a move toward 'passive' prevention, where the burden of daily adherence is removed from the patient. For South Africa, which faces one of the highest HIV burdens globally, this could significantly reduce new infection rates by overcoming the barriers of medication stigma and the difficulty of maintaining a strict daily regimen.
